Enrichment of macular pigment in subjects with age-related macular degeneration (AMD)

European Research Council (ERC)0 个研究点目标入组 150 人开始时间: 2012年8月22日最近更新: 2017年11月20日

适应症

试验速览

暂无简介。

•Current inclusion criteria as of 21/01/2014:
•1. Early stage AMD in at least one eye (between one and eight on the AREDS severity scale)
•2. Corrected distance visual acuity of = 6/12
•3. Spectacle prescription of = ±5D
•4. Have not taken eye-related dietary supplements containing the macular carotenoids (lutein, zeaxanthin and/or meso-zeaxanthin)
•5. No other ocular pathology
•6. No diabetes
•Previous inclusion criteria:
•1. Early stage non-visually consequential AMD in at least one eye (between one and eight on the Wisconsin severity scale) and no visually consequential (or late stage) AMD in the fellow eye
•2. Corrected distance visual acuity of = 6/12
•3. Spectacle prescription of = ±5D
•4. Have not taken eye-related dietary supplements containing the macular carotenoids (lutein, zeaxanthin and/or meso-zeaxanthin) in the previous twelve months
•5. No other ocular pathology
•6. No diabetes

•Current exclusion criteria as of 21/01/2014:
•1. No early stage AMD in at least one eye (between one and eight on the AREDS severity scale)
•2. Presence of late stage AMD in either eye
•3. Corrected distance visual acuity of < 6/12
•4. Spectacle prescription of > ±5D
•5. Recent history of carotenoid supplementation
•6. Presence of other ocular pathology
•7. Diabetes
•Previous exclusion criteria:
•1. No early stage non-visually consequential AMD in at least one eye (between one and eight on the Wisconsin severity scale)
•2. Presence of visually consequential (or late stage) AMD in either eye
•3. Corrected distance visual acuity of < 6/12
•4. Spectacle prescription of > ±5D
•5. Recent history of carotenoid supplementation
•6. Presence of other ocular pathology
•7. Diabetes

发起方

European Research Council (ERC)